Literature DB >> 20421778

Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma.

Minghao Zhong1, Patricia De Angelo, Lisa Osborne, Megan Keane-Tarchichi, Michael Goldfischer, Lisa Edelmann, Youfeng Yang, W Marston Linehan, Maria J Merino, Seena Aisner, Meera Hameed.   

Abstract

Both Xp11.2 translocation renal cell carcinoma (RCC) and alveolar soft part sarcoma (ASPS) are characterized by various translocations disrupting chromosome Xp11.2, which result in gene fusions involving the TFE3 transcription factor gene. Diagnostic tools to detect translocations involving the TFE3 gene on chromosome X would be valuable in the evaluation of these tumors. We developed a dual-color, break-apart fluorescence in situ hybridization (FISH) assay to identify the chromosomal break point in paraffin-embedded tissue. This assay was validated using 4 cases of Xp11.2 RCC [proven by karyotype and/or reverse-transcriptase polymerase chain reaction (RT-PCR)], 2 cases of ASPS (proven by karyotype or RT-PCR), the UOK109 cell line carrying the inv(X) (p11;q12), and several negative controls (both neoplastic and non-neoplastic). This break-apart FISH assay is a relatively quick procedure for detecting Xp11.2 RCC and ASPS translocations and can be applied to archival paraffin-embedded tissue.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20421778      PMCID: PMC7386799          DOI: 10.1097/PAS.0b013e3181dd577e

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  28 in total

1.  A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation.

Authors:  P Argani; A Hawkins; C A Griffin; J D Goldstein; M Haas; J B Beckwith; C B Mankinen; E J Perlman
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

2.  Clonal chromosome abnormalities in tumor cells from patients with sporadic renal cell carcinomas.

Authors:  G Kovacs; S Frisch
Journal:  Cancer Res       Date:  1989-02-01       Impact factor: 12.701

3.  The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25.

Authors:  M Ladanyi; M Y Lui; C R Antonescu; A Krause-Boehm; A Meindl; P Argani; J H Healey; T Ueda; H Yoshikawa; A Meloni-Ehrig; P H Sorensen; F Mertens; N Mandahl; H van den Berghe; R Sciot; P Dal Cin; J Bridge
Journal:  Oncogene       Date:  2001-01-04       Impact factor: 9.867

4.  High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors.

Authors:  Cathy D Vocke; Youfeng Yang; Christian P Pavlovich; Laura S Schmidt; Michael L Nickerson; Carlos A Torres-Cabala; Maria J Merino; McClellan M Walther; Berton Zbar; W Marston Linehan
Journal:  J Natl Cancer Inst       Date:  2005-06-15       Impact factor: 13.506

Review 5.  Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma.

Authors:  J R Gnarra; D R Duan; Y Weng; J S Humphrey; D Y Chen; S Lee; A Pause; C F Dudley; F Latif; I Kuzmin; L Schmidt; F M Duh; T Stackhouse; F Chen; T Kishida; M H Wei; M I Lerman; B Zbar; R D Klausner; W M Linehan
Journal:  Biochim Biophys Acta       Date:  1996-03-18

Review 6.  Alveolar soft-part sarcoma: a review and update.

Authors:  A L Folpe; A T Deyrup
Journal:  J Clin Pathol       Date:  2006-11       Impact factor: 3.411

7.  TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.

Authors:  Masumi Tsuda; Ian J Davis; Pedram Argani; Neerav Shukla; Gael G McGill; Makoto Nagai; Tsuyoshi Saito; Marick Laé; David E Fisher; Marc Ladanyi
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

8.  Alveolar soft part sarcoma--reciprocal translocation between chromosome 17q25 and Xp11. Report of a case with metastases at presentation and review of the literature.

Authors:  S Uppal; H Aviv; F Patterson; S Cohen; J Benevenia; S Aisner; M Hameed
Journal:  Acta Orthop Belg       Date:  2003-04       Impact factor: 0.500

9.  Mapping the X chromosome breakpoint in two papillary renal cell carcinoma cell lines with a t(X;1)(p11.2;q21.2) and the first report of a female case.

Authors:  J M Shipley; S Birdsall; J Clark; J Crew; S Gill; M Linehan; J Gnarra; S Fisher; I W Craig; C S Cooper
Journal:  Cytogenet Cell Genet       Date:  1995

10.  Melanotic Xp11 translocation renal cancers: a distinctive neoplasm with overlapping features of PEComa, carcinoma, and melanoma.

Authors:  Pedram Argani; Sebastian Aulmann; Zarir Karanjawala; Robert B Fraser; Marc Ladanyi; Maria M Rodriguez
Journal:  Am J Surg Pathol       Date:  2009-04       Impact factor: 6.394

View more
  30 in total

1.  Brain metastasis of crystal-deficient, CD68-positive alveolar soft part sarcoma: ultrastructural features and differential diagnosis.

Authors:  Matthew D Cykowski; John Hicks; David I Sandberg; Adriana Olar; Julia A Bridge; Patricia T Greipp; Patricia Navarro; Steven Kolodziej; Meenakshi B Bhattacharjee
Journal:  Ultrastruct Pathol       Date:  2014-09-30       Impact factor: 1.094

2.  Translocation renal cell carcinomas in adults: a single-institution experience.

Authors:  Minghao Zhong; Patricia De Angelo; Lisa Osborne; Alberto E Paniz-Mondolfi; Matthew Geller; Youfeng Yang; W Marston Linehan; Maria J Merino; Carlos Cordon-Cardo; Dongming Cai
Journal:  Am J Surg Pathol       Date:  2012-05       Impact factor: 6.394

3.  Xp11.2 translocation renal cell carcinoma with PSF-TFE3 rearrangement.

Authors:  Minghao Zhong; Paul Weisman; Bing Zhu; Maria Brassesco; Youfeng Yang; W Marston Linehan; Maria J Merino; David Zhang; Stephen Rohan; Dongming Cai; Ximing Yang
Journal:  Diagn Mol Pathol       Date:  2013-06

4.  Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.

Authors:  Nur P Damayanti; Justin A Budka; Heba W Z Khella; Mary W Ferris; Sheng Yu Ku; Eric Kauffman; Anthony C Wood; Khunsha Ahmed; Venkata Nithinsai Chintala; Remi Adelaiye-Ogala; May Elbanna; Ashley Orillion; Sreenivasulu Chintala; Chinghai Kao; W Marston Linehan; George M Yousef; Peter C Hollenhorst; Roberto Pili
Journal:  Clin Cancer Res       Date:  2018-07-30       Impact factor: 12.531

5.  t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases.

Authors:  Nathaniel E Smith; Peter B Illei; Mohamed Allaf; Nilda Gonzalez; Kerry Morris; Jessica Hicks; Angelo Demarzo; Victor E Reuter; Mahul B Amin; Jonathan I Epstein; George J Netto; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

Review 6.  The metabolic basis of kidney cancer.

Authors:  W Marston Linehan; Christopher J Ricketts
Journal:  Semin Cancer Biol       Date:  2012-06-13       Impact factor: 15.707

Review 7.  [The translocation carcinoma: A pediatric renal tumor also in adults].

Authors:  E Bruder; H Moch
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

8.  TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.

Authors:  Pedram Argani; Minghao Zhong; Victor E Reuter; John T Fallon; Jonathan I Epstein; George J Netto; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-06       Impact factor: 6.394

Review 9.  Oral alveolar soft part sarcoma in childhood and adolescence: report of two cases and review of literature.

Authors:  Prokopios P Argyris; Robyn C Reed; J Carlos Manivel; Dolores Lopez-Terrada; Jared Jakacky; Zuzan Cayci; Konstantinos I Tosios; Stefan E Pambuccian; Lester D R Thompson; Ioannis G Koutlas
Journal:  Head Neck Pathol       Date:  2012-09-08

10.  Xp11 translocation renal cell carcinoma in adults: a clinicopathological and comparative genomic hybridization study.

Authors:  Hong Zou; Xueling Kang; Li-Juan Pang; Wenhao Hu; Jin Zhao; Yan Qi; Jianming Hu; Chunxia Liu; Hongan Li; Weihua Liang; Xianglin Yuan; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.